Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
about
Role of insulin in the type 2 diabetes therapy: past, present and futureInsulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analoguesCommon standards of basal insulin titration in type 2 diabetesAssessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysisInitiation and Intensification Strategies in Type 2 Diabetes Management: A Comparison of Basal Plus and Premix RegimensSafety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysisEffect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes.The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling studyComparison of thrice-daily lispro 50/50 vs thrice-daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetesComparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: Systemic review and meta-analysesEfficacy of liraglutide therapy in Japanese type 2 diabetic patients insufficiently controlled with basal-supported oral therapy.Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study.Predictor variables and an equation for estimating HbA1c attainable by initiation of basal supported oral therapy.Initiating insulin therapy in type 2 diabetic patients failing on oral hypoglycemic agents: basal or prandial insulin? The APOLLO trial and beyond.Improvement of both fasting and postprandial glycemic control by the two-step addition of miglitol and mitiglinide to basal insulin therapy: a pilot study.Barriers to insulin initiation: the translating research into action for diabetes insulin starts project.Metabolic effects of Basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: registry-based observational study in clinical practice.Safety, tolerability, and efficacy of insulin aspart in people with type 2 diabetes, as biphasic insulin aspart or with Basal insulin: findings from the multinational, non-interventional a1chieve study.Total costs of basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: register-based observational study in clinical practice.Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: A systematic reviewRelationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials.Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009Continuous glucose monitoring with Humalog Mix 25 versus Humalog Mix 50, twice daily: a comparative pilot study -results from the Jikei-EValuation of insulin Lispro mixture on pharmacodynamics and glycemic VariancE (J-EVOLVE) study.Diet control to achieve euglycemia induces significant loss of heart and liver weight via increased autophagy compared with ad libitum diet in diabetic rats.Hidden complexities in assessment of glycemic outcomes: are quality rankings aligned with treatment?Initiating insulin as part of the Treating To Target in Type 2 Diabetes (4-T) trial: an interview study of patients' and health professionals' experiences.Weight considerations in pharmacotherapy for type 2 diabetesEvaluation of insulin regimens as an effective option for glycemic control in patients with type 2 diabetes: A propensity score-matched cohort study across Japan (JDDM31)Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetesPharmacological treatment of the pathogenetic defects in type 2 diabetes: the randomized multicenter South Danish Diabetes StudyManagement of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study.Observational study of the association of first insulin type in uncontrolled type 2 diabetes with macrovascular and microvascular disease.The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargineEfficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.Making Insulin Accessible: Does Inhaled Insulin Fill an Unmet Need?A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetesTreat-to-target trials: uses, interpretation and review of concepts.A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study.A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.
P2860
Q22241148-0D8311DB-DDDE-4EB2-AE59-80A3D4FF3808Q26861313-B30BB083-A3C6-4C1B-92F9-A8F51DE43BDFQ27009355-65466629-D7DD-478D-8074-DA0F4FB9090BQ28075335-F542ACB1-56E5-4C4E-8C38-16A647FF5AEDQ28077688-6EA5EEEA-D10B-46E3-AFE1-6588E9B6D95FQ28078467-9E4EAE4E-EFFE-4BE5-83EA-339A69B5334AQ30494654-52FA93B1-7430-429C-9696-A0B20068039DQ33508691-FE94A8AA-BEE0-4FC1-89A7-14B9EB840114Q33558371-743E0A01-D19C-494B-ABAA-BA3E155F52C6Q33585766-D7DE74C6-CD54-4624-8195-8C987987DAFCQ33587812-A735229F-1FB9-4EC7-B830-38173AF880D6Q33606579-C4D52C5B-A6C2-45FF-8912-2FBCC22C39D4Q33609805-E1BC79EE-7FE9-4BA3-8742-595C538A2FD9Q33610830-26422A0C-5671-4346-85A4-91661DECD55CQ33629805-F938FEA8-62A3-4DB2-AC3F-5257CE8C8559Q33751437-E0C4AC41-576D-4963-AD51-CD90EB7E6D20Q33785179-86F7635F-9F3E-4828-9CA5-5107D2DDC3B7Q33785202-8B02A414-DFE2-489D-B1F1-36178284AB3CQ33801252-E59AF8EB-BA5A-4CE9-89E6-3A466A61DAB0Q33871367-2C55737A-3998-48F7-82B6-B5E05D3F7A04Q33871459-A8FD04D0-F7F2-44DD-B4D8-C1B108871565Q33880303-A697B4F5-0C1F-4EF0-82C4-01CEF2F69319Q33911811-94887E91-E55E-4BC8-879D-2033E5BD14CEQ34116264-F4B2ABBB-F9DD-40C7-93AE-B0EF3DAD9767Q34153401-8B2CF505-57D2-4BC8-A1D0-9FDA6479F1B3Q34153449-7FF83600-7DE9-4FF4-AAEA-FC9CF2EC4B7AQ34159414-CFB519C7-3DBB-47BE-A640-22C86362CAD6Q34299641-21594BD6-480A-407D-8958-AACCDEB950E2Q34381425-B2DFAD93-3031-43F5-B451-88D3C9E9096DQ34422081-61EAAF14-208D-420A-9CC5-4B6647AE6041Q34457919-7288BE5C-C6CC-44D2-9000-D7985BBDC77BQ34468769-16BC126C-4F42-4767-A0B1-3D4F3665E568Q34482881-7A24F492-1CC5-4487-A7E6-FDC1EA6B125EQ34506998-7096617F-51F6-4850-8451-4141C0FF31C9Q34507342-93DC81CC-423C-4B6F-9348-045AAFB598C5Q34533154-58A3AA0D-57DD-431E-AD70-CF48936E7F8FQ34540958-28E718FE-D76D-48B3-90DB-B098785FB44CQ34540987-381DF936-1C26-4892-83DE-11C2E46D0D3CQ34565168-D9936175-1D6E-4391-B631-7FB91E2FB07CQ34583351-5BD8B6E4-E56F-43C7-ADDF-0D1D6B0E817A
P2860
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
@ast
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
@en
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
@nl
type
label
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
@ast
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
@en
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
@nl
prefLabel
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
@ast
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
@en
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
@nl
P2093
P50
P356
P1476
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
@en
P2093
4-T Study Group
Andrew J Farmer
Rury R Holman
P304
P356
10.1056/NEJMOA075392
P407
P577
2007-09-21T00:00:00Z